• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic’s AdaptivCRT implants chop follow-up care in half, study finds

Medtronic’s AdaptivCRT implants chop follow-up care in half, study finds

June 18, 2014 By Arezu Sarvestani

Medtronic's AdaptivCRT defibs cut follow-up care in half, study finds

Medtronic’s (NYSE:MDT) AdaptivCRT self-regulating defibrillators may help take a chunk out of healthcare costs by slashing certain follow-up care for patients with heart failure, according to the latest results from an ongoing analysis.

New results from the Adaptive CRT clinical trial (randomized, double-blind) showed a 55% reduction in atrial fibrillation-related "healthcare utilizations," such as hospitalizations, emergency department or clinic visits, compared with patients who received conventional biventricular pacing.

The AdaptivCRT self-regulating cardiac resynchronization therapy-defibrillators create tailored treatment regimens by adjusting automatically to a patient’s heart rhythms. Previous analyses have found that the proprietary sensing and adjustment algorithms may increase the appropriate therapy response rate and help reduce a patient’s risk of developing atrial fibrillation.

The new analyses, from data on 476 patients, found a dramatic reduction in follow-up care as well as a 61% reduction in the risk of atrial fibrillation-related problems, according to a Medtronic statement. Healthcare providers in the U.S. and Germany realized 12-month cost savings of $630 USD and €130, respectively, nearly all of which came from a reduction in hospitalizations.

"The study results are clear in showing that CRT devices with adaptive algorithms reduce the risk of atrial fibrillation adverse events and related costs," Lüdenscheid Hospital cardiology head Dr. Prof. Dr. Med. Bernd Lemke said on Medtronic’s behalf. "On an individual level, the algorithm’s personalized therapy helps keep more patients out of the hospital. On a system-level, this results in savings and less use of healthcare resources."

Reductions in follow-up care is a prime selling point for hospitals in the U.S., especially as federal health programs roll back reimbursement for 30-day patient readmissions.

The AdaptivCRT technology is already available in Medtronic’s Viva CRT-D and Viva CRT-P devices. Medtronic’s Viva devices won CE Mark approval in the European Union in 2012 and approval from the FDA last year.*

*Corrected: The FDA win for the Viva device was a premarket approval, not 510(k) clearance.

Filed Under: News Well Tagged With: Cardiac Rhythm Management, Clinical Trials, Minnesota

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy